BRIEFING: Key Aspergillosis Themes from TIMM 2025

(For non-specialist professionals and patient advocates)

The 2025 TIMM abstracts show continuing concern around rising azole resistance, emerging Aspergillus species, and ongoing diagnostic challenges in chronic and invasive disease. A growing number of studies highlight the importance of environmental surveillance, molecular diagnostics, and recognising less typical at-risk groups such as people with viral pneumonias, COPD, and those receiving new biologics or immunomodulators.

Clinical messages for non-specialists:

1. Environmental and agricultural azole use remains a major resistance driver

Multiple studies (Latin America, Spain, Belgium) confirm that agricultural triazoles continue to select for resistant Aspergillus fumigatus. Resistant strains do reach hospital environments, including ICUs and haematology wards.

Implication:
Healthcare teams must remain alert to azole treatment failure, consider susceptibility testing, and recognise that resistance is no longer rare.

2. Cryptic and emerging Aspergillus species are increasingly recognised

Traditional diagnostics often miss less common species such as A. turcosus, A. hiratsukae, and A. pseudodeflectus.
MALDI-TOF may misidentify these species; molecular sequencing gives clearer answers.

Implication:
If disease progresses unexpectedly or does not respond to standard therapy, consider the possibility of an unusual Aspergillus species.

3. New risk groups for invasive aspergillosis

Studies from Europe highlight increasing cases of IA in:

Severe viral pneumonia (RSV, influenza, COVID-19)
Patients receiving modern biologics (tocilizumab, oblituzumab)
Children with haematological cancers
Lung transplant recipients (with late-onset IA)
COPD patients or those without classical immunosuppression

Implication:
Non-specialists should be aware that IA is no longer confined to neutropenia or transplant; clinicians should maintain suspicion in severely unwell respiratory patients.

4. Diagnostic testing improves when multiple methods are combined

Several abstracts show:

Combining galactomannan + PCR on BAL substantially improves detection.
Western blot + IgE/IgG pairing improves ABPA and CPA diagnosis.
ICAP alone has a very high false-positive rate.

Implication:
Do not rely on a single test. ABPA and CPA particularly require combined clinical + radiological + serological evidence.

5. Aspergillus biofilms remain important and difficult to treat

Biofilm studies show that:

Mature Aspergillus biofilms are highly drug-tolerant.
Co-habiting bacteria (e.g., Stenotrophomonas maltophilia) enhance biofilm stability.
Biofilms may explain chronic, relapsing airways disease patterns in CPA/ABPA/bronchiectasis patients.

Implication:
Patients with chronic or relapsing symptoms may have biofilm-driven inflammation and reduced antifungal penetration.

6. Mortality in invasive disease remains high

Reports from transplant units and paediatric oncology centres show:

58% mortality in paediatric invasive aspergillosis.
6% IA-related mortality in lung transplant cohort (with many later indirect deaths).
Early diagnosis and correct drug choice remain critical.

Implication:
Prompt recognition and appropriate antifungal selection (including combination therapy when needed) remain essential.

TABLE OF ALL RELEVANT ASPERGILLUS / ASPERGILLOSIS / ANTIFUNGAL ABSTRACTS

(From full-document review; includes resistance, diagnostics, epidemiology, biofilms, and case reports)

ID	Title / Topic	Type
Latin America Environment Study	Environmental azole resistance across 12 countries; 2152 A. fumigatus isolates	Environmental / Resistance
P026	A. fumigatus in Belgian hospitals: triazole resistance surveillance	Environmental / Clinical resistance
27-Year Spain Study (Ashraph et al.)	118 azole-resistant strains; multiple fungicide resistance mechanisms	Environmental / Genomics / Resistance
P317	Invasive sinus aspergillosis by A. hiratsukae in transplant recipient	Case report / Cryptic species
CPA Case – A. pseudodeflectus	Chronic necrotising CPA from rare Usti-section Aspergillus	CPA / Case
P389	Metagenomics confirming mixed Aspergillus infection (A. niger + A. terreus)	Diagnostics / Mixed infection
A. turcosus fatal IA case	Cryptic fumigati species causing fatal invasive infection	Case report / Cryptic species
P213	Difficult CPA diagnosis in COPD	CPA / Clinical
P224	Recurrent maxillary sinus aspergilloma with bone destruction	Sinus aspergillosis
P267	Epidemiology of Aspergillus-related lung disease (IPA, CPA, ABPA) in Marseille	Epidemiology
P252	Species distribution in 418 filamentous fungal infections – Aspergillus dominant	Epidemiology
Lung transplant cohort (1100 pts)	IPA incidence, risk factors, treatment outcomes	IPA / Transplant
Paediatric oncology IA cohort	43 cases; high mortality	Paediatric IA
P352	RSV-associated invasive pulmonary aspergillosis	Viral-associated IPA
Asp-WB + ICAP combination study	Improved diagnosis of ABPA/CPA; ICAP alone widely false positive	Diagnostics
Molecular vs GM vs culture study	PCR on BAL highly accurate for Aspergillus detection	Diagnostics
P154	Lateral flow assay (LFA) for Aspergillus in sputum/serum	Diagnostics
Mixed biofilm GAG study	Bacterial–fungal synergy increases biofilm resilience	Biofilms / Pathogenesis
P090	Aspergillus biofilm extracellular matrix across strains and mixed species	Biofilms
TB–fungal co-infection (Aspergillus rare but present)	7 Aspergillus co-infections among TB cohort	Epidemiology

TABLE OF ALL RELEVANT ASPERGILLUS / ASPERGILLOSIS / ANTIFUNGAL ABSTRACTS WITH SUMMARIES

ENVIRONMENTAL & RESISTANCE STUDIES

1. Latin America Environmental Study

Topic: Air sampling in 12 countries: azole-resistant A. fumigatus widely present.
Summary: Large-scale citizen-science sampling found resistant Aspergillus spores across cities, rural sites, and farms. Confirms that humans inhale resistant strains from the environment, not just healthcare settings.

**2. P026 — A. fumigatus in Belgian Hospitals**

Topic: Hospital environmental surveillance for triazole resistance.
Summary: Resistant strains were found inside clinical areas, indicating they can enter hospitals via outdoor air. Important for infection control planning and for selecting appropriate antifungal therapy.

3. 27-Year Spanish Resistance Evolution Study (Ashraph et al.)

Topic: 118 azole-resistant isolates characterised over nearly three decades.
Summary: Shows a clear link between agricultural fungicide exposure and clinical resistance. Some strains developed multi-fungicide resistance, not just medical azoles.

CLINICAL CASES & CRYPTIC SPECIES

**4. P317 — A. hiratsukae Sinusitis in Transplant Patient**

Topic: Rare Aspergillus species causing invasive sinus disease.
Summary: Standard tests misidentified the fungus. Molecular sequencing confirmed a rare species. Highlights the need for advanced diagnostics when patients fail to improve.

5. CPA Case — A. pseudodeflectus

Topic: Chronic pulmonary aspergillosis caused by an unusual species.
Summary: Routine ID methods mislabelled the organism. Demonstrates cryptic species can cause CPA and may have different antifungal patterns.

**6. Mixed A. niger + A. terreus Wound Infection (Metagenomics)**

Topic: Mixed Aspergillus infection detected only by sequencing.
Summary: Traditional culture missed the second species. Mixed infections may explain poor responses to treatment.

**7. A. turcosus Fatal IA Case**

Topic: Rare fumigati section species.
Summary: Standard MALDI-TOF misidentified the species. High mortality emphasises why correct species identification matters for appropriate antifungal choice.

8. P213 — CPA Misdiagnosed as COPD

Topic: Chronic necrotising CPA mimicking COPD exacerbations.
Summary: Symptoms and imaging resembled COPD flare-ups. Only biopsy and molecular tests confirmed CPA. Highlights need for fungal testing in patients with atypical COPD.

9. P224 — Recurrent Maxillary Sinus Aspergilloma

Topic: Aspergillus sinus infection with bone involvement.
Summary: Shows how aspergilloma can recur if fungal debris remains or anatomy predisposes to blockage. ENT review and sometimes surgery are essential.

EPIDEMIOLOGY & COHORT STUDIES

10. P267 — Aspergillus Lung Disease in Marseille

Topic: Mix of ABPA, CPA and IPA.
Summary: Many ABPA cases were untreated or misclassified. Underlines widespread under-diagnosis and need for education of clinicians.

11. P252 — Species Distribution in 418 Fungal Infections

Topic: Large clinical review of filamentous fungi.
Summary: Aspergillus was the most common mould isolated, with A. fumigatus dominating. Confirms its continuing role as the most clinically significant mould.

12. Lung Transplant Cohort (1100 patients)

Topic: IA incidence, timing, species distribution and outcomes.
Summary: Early IA occurred from colonisation or environmental exposure; late IA linked to rejection and immunosuppression. Mortality remains high.

13. Paediatric Oncology IA Cohort

Topic: 43 children with invasive aspergillosis.
Summary: Mortality 58%. Mostly in acute leukemias. Underscores need for rapid testing and early therapy in children.

14. P352 — RSV-Associated Invasive Aspergillosis

Topic: Expanding “viral-associated pulmonary aspergillosis” beyond influenza and COVID-19.
Summary: RSV can also predispose immune-competent patients to IA. Important emerging risk category.

DIAGNOSTICS

15. Asp-Western Blot + IgE/IgG Combination Study

Topic: Diagnostic accuracy for ABPA/CPA.
Summary: Combining tests improves accuracy. ICAP alone is unreliable, with high false positives.

16. Molecular vs GM vs Culture Study (Italy)

Topic: Diagnostic accuracy of PCR on BAL.
Summary: PCR in BAL fluid was the most sensitive method. Combining PCR + galactomannan gave the best results.

17. P154 — Lateral Flow Assay (LFA)

Topic: Rapid point-of-care test for Aspergillus antigen.
Summary: Good performance in pre-treated sputum and serum. Promising as a rapid triage tool.

BIOFILM & PATHOGENESIS

18. Mixed Biofilm Study — A. fumigatus + S. maltophilia

Topic: How fungi and bacteria form stabilised mixed biofilms.
Summary: The Aspergillus biofilm sugar GAG enhances bacterial adhesion. Explains why some patients have stubborn, relapsing infections.

19. P090 — Biofilm Extracellular Matrix Study

Topic: Differences in matrix structure across Aspergillus strains.
Summary: Certain strains form thicker, more drug-resistant biofilms. May explain different patient responses to the same antifungal treatment.

TB CO-INFECTION (Aspergillus-related)

20. TB + Fungal Co-infection Study

Topic: TB patients screened for fungal disease.
Summary: Aspergillus infections were rare but present. Highlights need to consider CPA in chronic post-TB lung damage.

Path: Start » Weekly Updates » TIMM 2025 – Aspergillosis-Relevant Highlights for Non-Specialist Professionals

TIMM 2025 – Aspergillosis-Relevant Highlights for Non-Specialist Professionals